PD-L1 is an immunoinhibitory molecule that suppresses the activation of T cells, leading to
the progression of tumors. Overexpression of PD-L1 in cancers such as gastric cancer …

Background Numerous agents targeting PD-L1/PD-1 check-point are in clinical
development. However, the correlation between PD-L1expression and prognosis of solid …

PD-L1 expression is a feature of Epstein-Barr virus (EBV) associated malignancies such as
nasopharyngeal carcinoma (NPC). Here, we found that EBV-induced latent membrane …

T-cell checkpoint inhibition has a profound impact on cancer care and the programmed cell
death protein 1 (PD-1)–targeted antibodies nivolumab and pembrolizumab have been two …

Exosomes are membrane vesicles which offer potential as blood derived biomarkers for
malign tumors in clinical practice. Pancreatic cancer is counted among cancer diseases with …

Background: An increasing number of studies have examined the ability of programmed
death-ligand 1 (PD-L1) to function as a marker for tumor prognosis. However, whether PD …

Background: The clinical and prognostic value of programmed death-ligand 1, PD-L1, in
glioblastoma remains controversial. The present study aimed to identify the expression of …

The expression of programmed cell death 1 (PD-1) and its ligand (PD-L1) has been
observed in various epithelial-originated malignancies. However, whether the expression of …

Over expression of B7-H1 (also named PDL-1 or CD 274) molecule in cancer has been
linked to worse prognosis and resistance to anti-cancer therapies in several malignancies …

Abstract Programmed death-ligand 1 (PD-L1) is thought to play a critical role in immune
escape by cancer, but whether PD-L1 expression can influence prognosis of patients with …